Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - fampyra
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp40c8dbb155810b203735f0693961138c
identifier: http://ema.europa.eu/identifier
/EU/1/11/699/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Fampyra 10 mg prolonged-release tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-40c8dbb155810b203735f0693961138c
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/11/699/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - fampyra
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Fampyra contains the active substance fampridine which belongs to a group of medicines called potassium channel blockers. They work by stopping potassium leaving the nerve cells which have been damaged by MS. This medicine is thought to work by letting signals pass down the nerve more normally, which allows you to walk better.
Fampyra is a medicine used to improve walking in adults (18 years and over) with Multiple Sclerosis (MS) related walking disability. In multiple sclerosis, inflammation destroys the protective sheath around the nerves leading to muscle weakness, muscle stiffness and difficulty walking.
Do not take Fampyra
if you are allergic to fampridine or any of the other ingredients of this medicine (listed in section 6)
if you have a seizure or have ever had a seizure (also referred to as a fit or convulsion)
if your doctor or nurse has told you that you have moderate or severe kidney problems
if you are taking a medicine called cimetidine
if you are taking any other medicine containing fampridine. This may increase your risk of serious side effects
Tell your doctor and do not take Fampyra if any of these apply to you.
Warnings and precautions
Talk to your doctor or pharmacist before taking Fampyra:
if you feel aware of your heartbeat (palpitations)
if you are prone to infections
if you have any factors or are taking any medicine which affects your risk of fits (seizure).
if you have been told by a doctor that you have mild problems with your kidneys
if you have history of allergic reactions
You should use a walking aid, such as a cane, as needed because this medicine may make you feel dizzy or unsteady this may result in an increased risk of falls.
Tell your doctor before you take Fampyra if any of these apply to you.
Children and adolescents
Do not give this medicine to children or adolescents under the age of 18 years.
Elderly
Before starting treatment and during treatment your doctor may check that your kidneys are working properly.
Other medicines and Fampyra
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Do not take Fampyra if you are taking any other medicine containing fampridine.
Other medicines that affect the kidneys
Your doctor will be especially careful if fampridine is given at the same time as any medicine which may affect how your kidneys eliminate medicines for example carvedilol, propranolol and metformin.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist before for advice before taking this medicine.
Fampyra is not recommended during pregnancy.
Your doctor will consider the benefit of you being treated with Fampyra against the risk to your baby.
You should not breast-feed whilst taking this medicine.
Driving and using machines
Fampyra may have an effect on people s ability to drive or use machines, it can cause dizziness. Make sure you are not affected before you start driving or use machinery.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Fampyra is only available by prescription and under the supervision of doctors experienced in MS.
Your doctor will give you an initial prescription for 2 to 4 weeks. After 2 to 4 weeks the treatment will be reassessed.
The recommended dose is
One tablet in the morning and one tablet in the evening (12 hours apart). Do not take more than two tablets in a day. You must leave 12 hours between each tablet. Do not take the tablets more often than every 12 hours.
Fampyra is for oral use.
Swallow each tablet whole, with a drink of water. Do not divide, crush, dissolve, suck or chew the tablet. This may increase your risk of side effects.
This medicine should be taken without food, on an empty stomach.
If your Fampyra is supplied in bottles, the bottle will also contain a desiccant. Leave the desiccant in the bottle, do not swallow it.
If you take more Fampyra than you should
Contact your doctor immediately if you take too many tablets. Take the Fampyra box with you if you go to see the doctor. In overdose you may notice sweating, minor shaking (tremor), dizziness, confusion, memory loss (amnesia) and fits (seizure). You may also notice other effects not listed here.
If you forget to take Fampyra
If you forget to take a tablet, do not take two tablets at once to make up for a missed dose. You must always leave 12 hours between each tablet.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you have a seizure, stop taking Fampyra and tell your doctor immediately.
If you experience one or more of the following allergic (hypersensitivity) symptoms: swollen face, mouth, lips, throat or tongue, reddening or itching of the skin, chest tightness and breathing problems stop taking Fampyra and see your doctor immediately.
Side effects are listed below by frequency:
Very common side effects
May affect more than 1 in 10 people:
Common side effects
May affect up to 1 in 10 people:
Uncommon side effects
May affect up to 1 in 100 people
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the package after EXP. The expiry date refers to the last day of that month.
Store below 25 C. Store the tablets in the original package in order to protect from light and moisture.
If your Fampyra is supplied in bottles, only one bottle should be opened at a time. After first opening use within 7 days.
Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Fampyra contains
The active substance is fampridine. Each prolonged-release tablet contains 10 mg of fampridine
The other ingredients are: Tablet core: hypromellose, microcrystalline cellulose, silica colloidal anhydrous, magnesium stearate; film coat: hypromellose, titanium dioxide (E-171), polyethylene glycol What Fampyra looks like and contents of the pack
Fampyra is an off-white, film coated, oval biconvex 13 x 8 mm prolonged-release tablet with A10 on one side.
Fampyra is supplied in either blister packs or bottles.
Bottles
Fampyra comes in HDPE (high-density polyethylene) bottles. Each bottle contains 14 prolonged- released tablets and a silica gel desiccant. Each pack contains 28 prolonged-released tablets (2 bottles) or 56 prolonged-released tablets (4 bottles).
Blisters
Fampyra comes in foil blisters of 14 prolonged-released tablets each. Each pack contains 28 prolonged-released tablets (2 blisters) or 56 prolonged-released tablets (4 blisters).
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Biogen Netherlands B.V. Prins Mauritslaan 1171 LP Badhoevedorp The Netherlands
Manufacturer
Alkermes Pharma Ireland Ltd, Monksland, Athlone, Co. Westmeath, Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Biogen Belgium N.V./S.A. T l/Tel: +32 2 219 12 Lietuva Biogen Lithuania UAB Tel: +37 0 5 259 6
Te .: +359 2 962 12 Luxembourg/Luxemburg Biogen Belgium N.V./S.A. T l/Tel: +32 2 219 12 esk republika Biogen (Czech Republic) s.r.o. Tel: +420 255 706 Magyarorsz g Biogen Hungary Kft. Tel.: +36 (1) 899 9Danmark Biogen (Denmark) A/S Tlf: +45 77 41 57 Malta Pharma MT limited Tel: +356 213 37008/9
Deutschland Biogen GmbH Tel: +49 (0) 89 99 6Nederland Biogen Netherlands B.V. Tel: +31 20 542 2Eesti Biogen Estonia O
Tel: +372 618 9Norge Biogen Norway AS Tlf: +47 23 40 01
Genesis Pharma SA : +30 210 8771 sterreich Biogen Austria GmbH Tel: +43 1 484 46 Espa a Biogen Spain SL Tel: +34 91 310 7Polska Biogen Poland Sp. z o.o. Tel.: +48 22 351 51 France Biogen France SAS T l: +33 (0)1 41 37 95 Portugal Biogen Portugal Sociedade Farmac utica Unipessoal, Lda Tel: +351 21 318 8Hrvatska Biogen Pharma d.o.o. Tel: +385 (0) 1 775 73 Rom nia Johnson & Johnson Romania S.R.L. Tel: +40 21 207 18 Ireland Biogen Idec (Ireland) Ltd. Tel: +353 (0)1 463 7Slovenija Biogen Pharma d.o.o. Tel: +386 1 511 02 sland Icepharma hf S mi: +354 540 8Slovensk republika Biogen Slovakia s.r.o. Tel: +421 2 323 340 Italia Biogen Italia s.r.l. Tel: +39 02 584 9Suomi/Finland Biogen Finland Oy Puh/Tel: +358 207 401
Genesis Pharma (Cyprus) Ltd : +357 22765Sverige Biogen Sweden AB Tel: +46 8 594 113 Latvija Biogen Latvia SIA Tel: +371 68 688 United Kingdom (Northern Ireland) Biogen Idec (Ireland) Limited Tel: +44 (0) 1628 50 1This leaflet was last revised in
Other sources of information
You can get a larger print version of this leaflet by calling the local representatives (see list above).
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-40c8dbb155810b203735f0693961138c
Resource Composition:
Generated Narrative: Composition composition-en-40c8dbb155810b203735f0693961138c
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/11/699/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - fampyra
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp40c8dbb155810b203735f0693961138c
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp40c8dbb155810b203735f0693961138c
identifier:
http://ema.europa.eu/identifier
/EU/1/11/699/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Fampyra 10 mg prolonged-release tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en